



Corporate Headquarters  
Hikma Pharmaceuticals USA Inc.  
200 Connell Drive, 4<sup>th</sup> Floor  
Berkeley Heighs, NJ 07922

T 1.908.673.1030

**VIA ELECTRONIC MAIL**

Office of the Vermont Attorney General  
109 State Street  
Montpelier, Vermont 05609  
[ago.highcostprescriptiondrugs@vermont.gov](mailto:ago.highcostprescriptiondrugs@vermont.gov)

January 4, 2023

Dear Sir/Madam,

In compliance with 18 V.S.A. § 4637, Hikma Pharmaceuticals USA Inc. (“Hikma”) hereby provides the Office of Attorney General with notice that Hikma has introduced new generic prescription drugs (the “Products”) at a wholesale acquisition cost that is over the threshold set for a specialty drug under the Medicare Part D program. A schedule identifying such Products is set forth as Exhibit A.

Additionally, in compliance with 18 V.S.A. § 4637(c) as further refined by 18 V.S.A. § 4637 (d), Hikma hereby provides the following information which is in the public domain or publicly available:

- (1) A description of the marketing and pricing plans used in the launch of the new drug in the United States and internationally;
  - a. *These drugs are generic products; therefore no marketing and pricing plans are available. These products are sold in the United States only.*
- (2) The estimated volume of patients who may be prescribed the drug;
  - a. *The estimated average number of patients per month is unknown to Hikma.*
- (3) Whether the drug was granted breakthrough therapy designation or priority review by the FDA prior to final approval;
  - a. *Not applicable.*
- (4) The date and price of acquisition if the drug was not developed by the manufacturer;
  - a. *Hikma did not acquire these products.*

Finally, Hikma would like to confirm that: (i) the Office of the Attorney General has not yet provided a format for submissions under this section; and (ii) this notice is an appropriate means of submitting the required information.

Very truly yours,

*Heather S. Patrick*

Heather Skye Patrick  
Sr. Analyst, Legal Affairs



**EXHIBIT A**

<b>NDC</b>	<b>PRODUCT</b>	<b>DATE OF INTRO TO MARKET</b>	<b>WAC</b>
00054-9628-57	Sodium Oxybate OS, 0.5g/mL, 180mL bottle	1/1/2023	\$5,535.00